As of March 23, 2026, Kymera Therapeutics's top three insider holders are Bros. Advisors Lp Baker (Director, 7.96Mn shares), Venture Fund X, L.P. Atlas (TenPercentOwner, 5.50Mn shares), Nello Mainolfi (Chief Executive Officer, 666.20K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Bros. Advisors Lp Baker | 0 | 7,955,916 | 11 Dec, 2025 | |
| Venture Fund X, L.P. Atlas | 4,676,075 | 828,830 | 13 Mar, 2024 | |
| Nello Mainolfi | Chief Executive Officer | 666,195 | 0 | 25 Feb, 2026 |
| Bruce N. Jacobs | Chief Financial Officer | 232,588 | 0 | 04 Mar, 2026 |
| Jared Gollob | Chief Medical Officer | 117,134 | 0 | 04 Mar, 2026 |
| Noah Goodman | Chief Business Officer | 59,306 | 0 | 04 Mar, 2026 |
| Brian Adams | Chief Legal Officer | 56,625 | 0 | 04 Mar, 2026 |
| Elaine Caughey | Chief Business Officer | 18,986 | 0 | 03 Mar, 2023 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 20 Mar, 2026 | Pamela Esposito | Common Stock | A | 2,500 | $49.10 | 2,500 | D | M |
| 20 Mar, 2026 | Pamela Esposito | Common Stock | D | 700 | $77.71 | 1,800 | D | S |
| 20 Mar, 2026 | Pamela Esposito | Common Stock | D | 600 | $79.24 | 1,200 | D | S |
| 20 Mar, 2026 | Pamela Esposito | Common Stock | D | 1,200 | $79.94 | 0 | D | S |
| 20 Mar, 2026 | Pamela Esposito | Stock Option (Right to Buy) | D | 2,500 | $0.00 | 0 | D | M |
| 02 Mar, 2026 | Jared Gollob | Common Stock | A | 17,650 | $0.00 | 127,642 | D | A |
| 02 Mar, 2026 | Noah Goodman | Common Stock | A | 9,225 | $0.00 | 59,306 | D | A |
| 02 Mar, 2026 | Nello Mainolfi | Stock Option (Right to Buy) | A | 215,000 | $0.00 | 215,000 | D | A |
| 02 Mar, 2026 | Bruce N. Jacobs | Common Stock | A | 17,650 | $0.00 | 245,059 | D | A |
| 02 Mar, 2026 | Brian Adams | Common Stock | A | 4,125 | $0.00 | 56,625 | D | A |
| 02 Mar, 2026 | Noah Goodman | Stock Option (Right to Buy) | A | 18,450 | $0.00 | 18,450 | D | A |
| 02 Mar, 2026 | Brian Adams | Stock Option (Right to Buy) | A | 8,250 | $0.00 | 8,250 | D | A |
| 02 Mar, 2026 | Jared Gollob | Common Stock | D | 1,510 | $87.75 | 126,132 | D | S |
| 02 Mar, 2026 | Bruce N. Jacobs | Common Stock | D | 2,039 | $87.75 | 243,020 | D | S |
| 02 Mar, 2026 | Jared Gollob | Common Stock | D | 1,055 | $88.50 | 125,077 | D | S |
| 02 Mar, 2026 | Bruce N. Jacobs | Common Stock | D | 1,424 | $88.50 | 241,596 | D | S |
| 02 Mar, 2026 | Bruce N. Jacobs | Common Stock | D | 4,113 | $89.66 | 237,483 | D | S |
| 02 Mar, 2026 | Jared Gollob | Common Stock | D | 3,048 | $89.66 | 122,029 | D | S |
| 04 Mar, 2026 | Bruce N. Jacobs | Common Stock | D | 492 | $84.00 | 236,991 | D | S |
| 04 Mar, 2026 | Jared Gollob | Common Stock | D | 492 | $84.00 | 121,537 | D | S |